Search - tctmd.com

Displaying 141 - 160 of 213

Sort: Relevancy | Date

Presentation TCT 2015

Aortic Valve Patho-Biology: Anatomical Implications for TAVR Performance

Presenter: Raj Makkar, Michael J. Reardon, James M. McCabe

October 13, 2015

Presentation TCT 2015

Intra-Procedural Echo Guidance in TAVR Procedures

Presenter: Raj Makkar, Michael J. Reardon, Rebecca T. Hahn

October 13, 2015

Presentation TCT 2015

Practical Echo Reading and Analysis of Aortic Annulus and Associated Structures

Presenter: Raj Makkar, Michael J. Reardon, Rebecca T. Hahn

October 13, 2015

Presentation TCT 2015

The Human Aortic Valve: Technical Landmarks and Considerations for TAVR Implantation

Presenter: Raj Makkar, Michael J. Reardon, James M. McCabe

October 13, 2015

Presentation TCT 2015

Vascular Access and Closure Techniques: A Step Wise Approach

Presenter: Raj Makkar, Michael J. Reardon, Torsten P. Vahl

October 13, 2015

News Conference News TCT 2015

Updates to CoreValve Extreme Risk Study Encouraging

October 13, 2015

News Industry News

Medtronic CoreValve® System Shows Positive Clinical Outcomes in New Patient Populations

October 13, 2015

Presentation TCT 2015

Poor Femoral Access and TAVR (Alternative Access): Thoughtful Commentary on the Case

Presenter: Howard C. Herrmann, Patrick T. O'Gara, Michael J. Reardon

October 12, 2015

Presentation TCT 2015

InSeal: Intravascular Closure Device

Presenter: Alain G. Cribier, Eberhard Grube, Robert J. Applegate, Stephen J.D. Brecker, Todd J. Brinton, Philippe Généreux, A. Pieter Kappetein, Michael J. Reardon, Josep Rodés-Cabau

October 12, 2015

Presentation TCT 2015

Updates From the US CoreValve Studies 1: Follow-up From the Extreme and High-Risk Subgroups

Presenter: Samir R. Kapadia, Jeffrey J. Popma, Michael J. Reardon

October 11, 2015

News Daily News

Survival Benefit of CoreValve in High-Risk Patients Persists at 2 Years

July 07, 2015

News Daily News

El Beneficio sobre la Supervivencia de CoreValve en Pacientes de Alto Riesgo se Mantiene a los 2 Años

July 07, 2015

Presentation

2-Year Outcomes in Patients Undergoing Surgery or Self-Expanding TAVR

Presenter: Michael J. Reardon

July 06, 2015

Presentation TVT 2015

A Surgeons View: Will I Be in the Room in the Future?

Presenter: Susheel K. Kodali, David A. Wood, Michael J. Reardon

June 06, 2015

Presentation TVT 2015

CoreValve US 2-Year Follow-up

Presenter: Michael J. Reardon

June 05, 2015

Presentation TVT 2015

The Importance of Correct Valve Sizing in Surgical and Transcatheter AVR

Presenter: Jonathon A. Leipsic, Jeffrey J. Popma, Michael J. Reardon

June 05, 2015

Presentation TVT 2015

Thoughtful Commentary: Poor Femoral (Alternative) Access and TAVR

Presenter: Neil E. Moat, Allan Schwartz, Michael J. Reardon

June 05, 2015

Presentation TVT 2015

Case Examples and Discussion

Presenter: Ted Feldman, Michael J. Reardon

June 04, 2015

Presentation TVT 2015

Direct Aortic TAVR: Optimal Technique and Complication Management

Presenter: Raj Makkar, Mathew Williams, Michael J. Reardon

June 04, 2015

Presentation ACC 2015

A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis Deemed at Increased Risk for Surgery 2-Year Outcomes

Presenter: Michael J. Reardon

March 15, 2015

Advertisement

Aortic Valve Patho-Biology: Anatomical Implications for TAVR Performance

Intra-Procedural Echo Guidance in TAVR Procedures

Practical Echo Reading and Analysis of Aortic Annulus and Associated Structures

The Human Aortic Valve: Technical Landmarks and Considerations for TAVR Implantation

Vascular Access and Closure Techniques: A Step Wise Approach

Updates to CoreValve Extreme Risk Study Encouraging

Medtronic CoreValve® System Shows Positive Clinical Outcomes in New Patient Populations

Poor Femoral Access and TAVR (Alternative Access): Thoughtful Commentary on the Case

InSeal: Intravascular Closure Device

Updates From the US CoreValve Studies 1: Follow-up From the Extreme and High-Risk Subgroups

Survival Benefit of CoreValve in High-Risk Patients Persists at 2 Years

El Beneficio sobre la Supervivencia de CoreValve en Pacientes de Alto Riesgo se Mantiene a los 2 Años

2-Year Outcomes in Patients Undergoing Surgery or Self-Expanding TAVR

A Surgeons View: Will I Be in the Room in the Future?

CoreValve US 2-Year Follow-up

The Importance of Correct Valve Sizing in Surgical and Transcatheter AVR

Thoughtful Commentary: Poor Femoral (Alternative) Access and TAVR

Case Examples and Discussion

Direct Aortic TAVR: Optimal Technique and Complication Management

A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis Deemed at Increased Risk for Surgery 2-Year Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content